Self-adhesive low-level light therapy in women with primary dysmenorrhea

Primary tabs

NEWS
Self-adhesive low-level light therapy in women with primary dysmenorrhea

Dysmenorrhea is the medical term used for painful menstruation. It usually begins around the time of beginning of menstruation and the symptoms typically last less than three days. The pain usually occurs in the pelvis or lower abdomen. Other symptoms may include back pain, diarrhea or nausea.

Primary dysmenorrhea is commonly menstrual cramps that are recurrent and are not due to other diseases. Pain usually begins 1-2 days before or when menstrual bleeding starts and is felt in the lower abdomen, back or thighs. Pain can range from mild to severe, can typically last 12 to 72 hours. Common menstrual cramps usually become less painful as a women ages and may stop entirely if the woman has a baby. Various therapies can also be given to reduce the pain. To evaluate the efficacy and safety of low level light therapy in women with primary dysmenorrhea, a multi-center prospective, randomized, double-blind, placebo-controlled clinical trial was conducted with patients of 18-35 years of age with primary dysmenorrhea.

Patients were randomized using a computer-generated sequence to receive low-level light therapy using the Color DNA-WSF device or to receive placebo treatment with a dummy device. The severity of menstrual pain, assessed using a visual analog scale, were the primary outcomes and were evaluated at baseline and during every menstrual cycle for 3 months following treatment. Patients who received more than one application of treatment were included in analysis. Patients and investigators were masked to the treatment assignments.

Overall, 44 patients were assigned to each group. At final study visit, the reduction in scores using a visual analog scale was significantly greater in patients who received low-level light therapy than among those in the controlled group. After the analysis, no serious adverse events occurred. At the end, it was concluded that the low level therapy could be an effective, safe treatment modality for women with primary dysmenorrhea.

International Journal of Gynecology and Obstetrics
Log in or register to post comments